Ryosuke Hayami

474 total citations
21 papers, 369 citations indexed

About

Ryosuke Hayami is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Ryosuke Hayami has authored 21 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Ryosuke Hayami's work include DNA Repair Mechanisms (6 papers), Breast Cancer Treatment Studies (6 papers) and HER2/EGFR in Cancer Research (5 papers). Ryosuke Hayami is often cited by papers focused on DNA Repair Mechanisms (6 papers), Breast Cancer Treatment Studies (6 papers) and HER2/EGFR in Cancer Research (5 papers). Ryosuke Hayami collaborates with scholars based in Japan and Singapore. Ryosuke Hayami's co-authors include Tomohiko Ohta, Wenwen Wu, Mamoru Fukuda, Toru Nishikawa, Hiroyuki Nishikawa, Ko Sato, Haruki Ogata, Yasuyuki Kojima, Ichiro Maeda and Koichiro Tsugawa and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ryosuke Hayami

17 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryosuke Hayami Japan 8 254 101 75 70 56 21 369
Dane Cheasley Australia 11 166 0.7× 124 1.2× 57 0.8× 85 1.2× 20 0.4× 19 276
Wolfgang Gruber Austria 9 272 1.1× 80 0.8× 49 0.7× 39 0.6× 13 0.2× 12 338
Jiehua He China 10 151 0.6× 120 1.2× 19 0.3× 157 2.2× 25 0.4× 18 353
T Noguchi France 7 153 0.6× 90 0.9× 127 1.7× 135 1.9× 15 0.3× 9 317
Carliann M. Costanzo United States 4 170 0.7× 189 1.9× 24 0.3× 59 0.8× 27 0.5× 5 352
Makia J. Marafie Kuwait 11 142 0.6× 37 0.4× 154 2.1× 79 1.1× 27 0.5× 28 279
Alessandra Rossi Italy 9 300 1.2× 75 0.7× 47 0.6× 40 0.6× 10 0.2× 14 362
David Purdie Australia 6 114 0.4× 110 1.1× 21 0.3× 61 0.9× 21 0.4× 7 248
Mio Yamamoto‐Sugitani Japan 10 219 0.9× 94 0.9× 12 0.2× 65 0.9× 11 0.2× 18 363
Valentina Fragliasso Italy 9 176 0.7× 74 0.7× 19 0.3× 46 0.7× 10 0.2× 25 295

Countries citing papers authored by Ryosuke Hayami

Since Specialization
Citations

This map shows the geographic impact of Ryosuke Hayami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryosuke Hayami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryosuke Hayami more than expected).

Fields of papers citing papers by Ryosuke Hayami

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryosuke Hayami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryosuke Hayami. The network helps show where Ryosuke Hayami may publish in the future.

Co-authorship network of co-authors of Ryosuke Hayami

This figure shows the co-authorship network connecting the top 25 collaborators of Ryosuke Hayami. A scholar is included among the top collaborators of Ryosuke Hayami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryosuke Hayami. Ryosuke Hayami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Sato, Ai, et al.. (2024). Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients. SHILAP Revista de lepidopterología. 17(1). 208–216.
3.
Yamaguchi, Kei, et al.. (2023). Acquired Treatment Resistance in a Patient with Metastatic PD-L1-Positive Breast Cancer and Germline BRCA1 Mutation. SHILAP Revista de lepidopterología. 16(1). 550–557.
4.
Matsunuma, Ryoichi, Ai Sato, Jason Yongsheng Chan, et al.. (2023). Enrichment of Immune-Related Genes in Aggressive Primary Breast Angiosarcoma: A Case Report. SHILAP Revista de lepidopterología. 16(1). 461–470. 2 indexed citations
5.
Usui, Yuki, Ryoichi Matsunuma, Kei Yamaguchi, et al.. (2021). Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast. Case Reports in Oncology. 14(3). 1536–1541. 3 indexed citations
6.
Yamaguchi, Kei, Ryoichi Matsunuma, Ryosuke Hayami, & Michiko Tsuneizumi. (2021). Large Breast Tumor Ulceration and Quality of Life in an 80-Year-Old Woman. Case Reports in Oncology. 14(1). 580–584. 1 indexed citations
7.
Yamaguchi, Kei, Ryoichi Matsunuma, Ryosuke Hayami, & Michiko Tsuneizumi. (2021). Comparison of the Modified Immunohistochemical Marker Score and 21-Gene Recurrence Score Assay in Patients with Estrogen Receptor-Positive Breast Cancer. Oncology. 100(3). 155–162. 2 indexed citations
8.
Matsunuma, Ryoichi, et al.. (2021). The Preferred Premedication Order to Prevent Infusion Reactions in Patients with Breast Cancer Receiving Pertuzumab Plus Trastuzumab and Docetaxel. Journal of Advances in Medicine and Medical Research. 24–30. 2 indexed citations
9.
Matsunuma, Ryoichi, et al.. (2020). <b><i>Pneumocystis</i></b> Pneumonia and Acute Kidney Injury Induced by Everolimus Treatment in a Patient with Metastatic Breast Cancer. Case Reports in Oncology. 13(1). 170–175. 2 indexed citations
10.
Yamaguchi, Kei, Ryoichi Matsunuma, Ryosuke Hayami, et al.. (2020). Concurrent Bowen’s Disease of the Nipple and Breast Cancer. Case Reports in Oncology. 13(3). 1410–1414. 4 indexed citations
12.
Wu, Wenwen, M. Okada, Ichiro Maeda, et al.. (2015). Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage. Cancer Science. 106(8). 1050–1056. 28 indexed citations
13.
Tsugawa, Koichiro, Kyoko Tsuchiya, Yasuyuki Kojima, et al.. (2015). Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: experience of 425 cases from a single institution. Breast Cancer. 23(6). 851–860. 45 indexed citations
14.
Wu, Wenwen, M. Okada, Ichiro Maeda, et al.. (2015). Class I HDAC inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.. Journal of Clinical Oncology. 33(15_suppl). e13552–e13552. 1 indexed citations
15.
Nagasawa, Satoi, Ichiro Maeda, Wenwen Wu, et al.. (2015). MED12 exon 2 mutations in phyllodes tumors of the breast. Cancer Medicine. 4(7). 1117–1121. 38 indexed citations
16.
Hayami, Ryosuke, et al.. (2015). [Thrombophlebitis in an Elderly Japanese Woman Treated with Tamoxifen for Breast Cancer].. PubMed. 42(10). 1203–5. 1 indexed citations
17.
Wu, Wenwen, Hiroyuki Nishikawa, Ryosuke Hayami, et al.. (2007). BRCA1 Ubiquitinates RPB8 in Response to DNA Damage. Cancer Research. 67(3). 951–958. 34 indexed citations
18.
Wu, Wenwen, Hiroyuki Nishikawa, Ryosuke Hayami, et al.. (2005). A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats. Cancer Letters. 233(1). 108–116. 25 indexed citations
19.
Hayami, Ryosuke, Ko Sato, Wenwen Wu, et al.. (2005). Down-regulation of BRCA1-BARD1 Ubiquitin Ligase by CDK2. Cancer Research. 65(1). 6–10. 53 indexed citations
20.
Sato, Ko, Ryosuke Hayami, Wenwen Wu, et al.. (2004). Nucleophosmin/B23 Is a Candidate Substrate for the BRCA1-BARD1 Ubiquitin Ligase. Journal of Biological Chemistry. 279(30). 30919–30922. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026